The Traderszone Network

Published in TZ Latest News 12 November, 2017 by The TZ Newswire Staff

Novartis highlights its differentiated late stage pipeline at the R&D update and investor event

London, November 13, 2017


Novartis has had a strong year in innovation with several key approvals and positive trial readouts. Today Novartis holds an R&D and investor update in London, which will provide deeper insights into key late-stage pipeline projects. In the Oncology business unit, Novartis is pursuing multiple indications for Kymriah, the first-in-class CAR-T therapy, and could further strengthen the oncology pipeline if the proposed acquisition of Advanced Accelerator Applications is closed.

read more